Ex-Baxalta Plant Gives Takeda First US Biologics Capacity
This article was originally published in PharmAsia News
Newly independent Baxalta has decided that one its domestic manufacturing facilities is surplus to requirements and is selling a biologics plant to Takeda that will become the Japanese firm's first in-house production facility in the US.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.